Abstract Episodes of neonatal hypoxia-ischemia (H
Introduction
The subventricular zone (SVZ), a remnant of the embryonic germinal zones, is a heterogeneous cellular population consisting of neural stem cells (NSCs) and progenitors of various potentialities. In the neonatal period, which is when large numbers of glial cells are being generated, the SVZ contains large numbers of bipotential and multipotential glial progenitors that produce immature astrocytes and oligodendrocyte progenitor cells (OPCs). These glial precursors migrate from the SVZ laterally to the adjacent striatum and dorsally to the white matter and the neocortical gray matter, giving rise to astrocytes, oligodendrocytes, and polydendrocytes [1] . The differentiation of a bipotential glial progenitor into either an astrocyte or an oligodendrocyte is regulated by a complex interaction of extrinsic and intrinsic cues. A fundamental question that remains unanswered is what are the extrinsic signals that affect the specification of the NSCs and progenitor cells of the SVZ during development and also after injury?
Hypoxia-ischemia (H-I) is a condition in which there is both lack of blood flow and low oxygen tension in the brain, leading to some degree of neurological deficit. Infants who survive episodes of H-I may develop cerebral palsy, epilepsy, developmental disabilities, or hypoxic-ischemic encephalopathy, a commonly used catchall phrase describing the nonspecific clinical picture after neonatal H-I. H-I is regarded as the major cause of brain damage in the term infant [2] [3] [4] . The pathophysiology of H-I involves adenosine triphosphate depletion, excitotoxicity, calcium toxicity, and free radical damage; however, inflammation also plays a significant role, contributing to both apoptosis and necrosis of many cells, notably the neurons and OPCs [5] [6] [7] [8] [9] [10] [11] . The particular depletion of OPCs in the white matter presents a major problem because neurogenesis is not sufficient without concurrent gliogenesis to restore functional recovery after injury [12] [13] [14] .
Studies in the adult brain after hypoxia show that the vascular endothelial growth factors (VEGF) and their corresponding receptors participate in hypoxia-induced neovascularization. Hypoxia-inducible factor-1 is a classic activator of VEGF production; however, other studies suggest roles for glucose deprivation, platelet-derived growth factor (PDGF), interleukin-1 beta, transforming growth factor beta 1, and tumor necrosis factor-alpha [15] . There are seven members of the VEGF family, A, B, C, D, and placentaderived growth factor, which bind to the tyrosine kinase receptors VEGFR-1 (Flt-1), VEGFR-2 (Flk-1 or KDR), VEGFR-3 (Flt-4), to neuropilin-1 and neuropilin-2, and to heparin sulfate proteoglycans [15] . While all of the VEGF isoforms regulate angiogenesis, recent evidence suggests that some isoforms promote the proliferation of other cell types. Studies show that VEGF-A stimulates the proliferation of astrocytes, Schwann cells, microglia, and cortical neuroblasts, as well as the proliferation, migration, and survival of NSCs in the SVZ, subgranular zone of the hippocampal dentate gyrus, and olfactory bulb [15] [16] [17] [18] [19] [20] [21] [22] [23] . Interestingly, Mani et al. showed that administrating VEGF-A to embryonic and adult rat neocortical explant cultures significantly increased the entire astroglial profile by increasing the percentage of mature GFAP+ cells, as well as immature nestin+ and vimentin+ cells via the Flt-1 receptor [24] . Whereas there have been several studies examining the effects of VEGF-A on central nervous system cells, there are few studies examining VEGF-C. One study conducted on VEGF-C-deficient mouse embryos showed selective loss of OPCs. Furthermore, VEGF-C induced optic nerve OPCs to proliferate, while VEGF-A did not induce bromodeoxyuridine (BrdU) incorporation [25] . Given that there is an aberrant production of astrocytes from SVZ precursors after H-I, we hypothesized that, among the VEGFs, VEGF-A might be uniquely produced in the SVZ after neonatal H-I. Furthermore, we sought to better characterize the effects of VEGF-C on different progenitor populations, specifically via the VEGFR-3 receptor.
Materials and Methods

Neonatal Hypoxia-Ischemia
All experiments were performed in accordance with the research guidelines set forth by the New Jersey Medical School and the Society for Neuroscience Policy on the use of animals in neuroscience research. Cerebral H-I was induced in P6 rats (day of birth being P0) by a permanent unilateral (right) common carotid artery cauterization under isoflurane anesthesia followed by systemic hypoxia [26] [27] [28] . The neck wound was sutured with surgical silk and the animals were returned to the dam to recover for 1.5 h. Animals were then prewarmed in jars for 20 min in a 37°C water bath. The pups were exposed to a humidified, hypoxic atmosphere (8 % O 2 /92 % N 2 ) at 37°C for 70 min, allowed to recover in room air, and then returned to their dams. Control animals were separated from the dam for the same amount of time as experimental animals, but were otherwise untouched.
ELISA
Tissue was isolated from microdissected SVZs and protein was extracted in lysis buffer (ice-cold phosphate-buffered saline (PBS) with 1 % Triton X-100, 0.1 % sodium dodecyl sulfate (SDS), 1 % protease inhibitor cocktail (Sigma P8340), 1 % Na 3 VO 4 , 1 % phenylmethylsulfonyl fluoride, 1 % sodium fluoride) followed by sonication and centrifugation. Matched antibody pairs for sandwich enzyme-linked immunosorbent assays (ELISAs) from R&D for rat VEGF-A (monoclonal antirat VEGF antibody (MAB564) and biotinylated antirat VEGF antibody (BAF564)) and human VEGF-C (monoclonal antihuman VEGF-C antibody (MAB752) and biotinylated antihuman VEGF-C antibody (BAF752)) were used on 10 μg of protein samples isolated from microdissected SVZs at various time points after injury. ELISAs were also used to determine protein concentrations of supernatants (100 μL) from spheroids, astrocytes, and microglia cultures placed under control or hypoxicglucopenic (HG) (2 % O 2 ) conditions for 2 h and supernatant collected after 18 h (for more information, see the "Microglia, Astrocyte, and Oligodendrocyte Progenitor Cultures" section).
Western Blot
Neurospheres, spheroids, OPCs, and astrocyte cultures were generated from neonatal rat brains using standard methods, as described in later subsections of the "Materials and Methods" section. Cells were collected by centrifugation and lysed with 1 % Triton X-100, 0.1 % SDS, and 1 % 0.1 M sodium orthovanadate and protease inhibitor cocktail (Roche Diagnostics) dissolved in PBS. The cells were sonicated and then centrifuged at 10,000 rpm for 15 min at 4°C. The protein concentration was quantified with the Pierce BCA Protein Assay Kit (ThermoScientific). Thirty micrograms of denatured protein was loaded onto a 4-12 % Novex NuPage Bis Tris Gel (Invitrogen) and then transferred to nitrocellulose (Invitrogen). Blots were probed with rabbit anti-VEGFR-3 (1:100, Santa Cruz) and mouse anti-β-actin (1:5,000, SigmaAldrich), washed, and incubated with secondary antibody against rabbit or mouse conjugated to horseradish peroxidase (1:2,500, Jackson ImmunoResearch Laboratories, West Grove, PA, USA). Signals were detected by enhanced chemiluminescence (PerkinElmer) and quantified using a UVP Bioimaging System. RNA Isolation, cDNA Reverse Transcriptase Reaction, and QRT-PCR Quantitative real-time polymerase chain reaction (QRT-PCR) was performed on microdissected SVZs. mRNAs were extracted from post-H-I rat SVZs at 6, 12, and 24 h, as well as days 2 and 7, and corresponding cDNAs were made using reverse transcription reaction. Custom-designed VEGF primers were optimized for SYBR Green chemistry and analyzed using an Applied Biosystems 7300 Real-Time PCR System Sequence Detection Systems v.1.2.3 (Foster City, CA, USA) ( Table 1 ). The ipsilateral (IL) hemisphere was compared to the contralateral (CL) hemisphere and nonhypoxic control (NHC) hemisphere. Applied Biosystems SDS 2.2.2 relative quantification (ΔΔCt) assay was used to quantify mRNA expression, and results are presented as RQ values.
Tissue Fixation and Histochemistry
Experimental animals were anesthetized with a mixture of ketamine (75 mg/kg) and xylazine (5 mg/kg) prior to perfusion with RPMI culture medium containing 6 U/ml heparin followed by 4 % paraformaldehyde (PFA) in 0.1 M phosphate buffer, pH 7.4. The brains were removed and immediately transferred to 4 % PFA overnight at 4°C. Brains were transferred to a 30 % sucrose solution for 24 h at 4°C followed by 4 h with fresh 30 % sucrose solution before being fixed frozen on a dry ice-ethanol slush in embedding medium and stored at −80°C.
Microvascular Luminal Areas
To quantify the luminal areas of SVZ microvessels, sections at recovery times spanning 4 to 48 h after H-I were stained with hematoxylin and eosin. Blood vessels were identified by morphology and chosen at random. Luminal areas were measured using IP Lab software (Scanalytics, Inc., Fairfax, VA, USA) on ×40 images. The sections from 4-h brains were stained for BrdU, tomato lectin, and 4′,6-diamidino-2-phenylindole (DAPI) to label proliferating blood vessel endothelial cells in hemispheres of H-I and NHCs. Corresponding vessels were measured from three random, nonadjacent SVZ sections and four animals at each time point.
Neurosphere and Spheroid Cell Cultures P4 rat pups were decapitated under sterile conditions and the brains were placed into PBS with 0.6 % glucose and 2 mM MgCl 2 . Incisions were made ∼2 mm from the anterior end of the brain and ∼3 mm posterior to the first cut. Blocks were transferred to fresh PBS-glucose-MgCl 2 . The region including the SVZ was microsurgically isolated, mechanically minced, and enzymatically dissociated using 1:4 dilution of Accutase (Innovative Cell Technologies, San Diego, CA, USA) at 37°C for 10 min. Neurospheres were generated using epidermal growth factor and fibroblast growth factor-2 (FGF-2) supplemented medium, whereas glial progenitors were propagated as spheroids using medium supplemented with 30 % B104 conditioned medium (CM) [29] . The ProN base growth medium contained Dulbecco's modified Eagle's medium (DMEM)/F12 supplemented with 10 ng/ ml D-biotin, 25 μg/ml insulin, 20 nM progesterone, 100 μM putrescine, 5 ng/ml selenium, 50 μg/ml apotransferrin, and 50 μg/ml gentamicin. Spheroids were generated in a 2 % O 2 , 5 % CO 2 , and 93 % N 2 37°C incubator. To dissociate or passage the spheroids, cells were treated with a pH-balanced enzyme solution containing collagenase III (0.002 g), papain (200 U), and DNase I (100 μL of 5 mg/mL stock) in 10 mL papain buffer (DMEM/F12 with 0.48 g HEPES, 0.02 g ethylenediaminetetraacetic acid [EDTA], and 0.0175 g L-cysteine). Differentiation of spheres was performed after dissociation with/without growth factor treatments in N2B2 media [ProN supplemented with 0.66 mg/ mL bovine serum albumin (BSA) and 0.5 % fetal bovine serum (FBS)] for 72 h.
Microglia, Astrocyte, and Oligodendrocyte Progenitor Cultures
Newborn Sprague-Dawley rat forebrain cortices were enzymatically digested with trypsin and DNase I and then mechanically dissociated prior to plating in MEM containing 10 % FBS with antibiotics as previously described [30] . The mixed glial cells were grown in T75 flasks until they were confluent (10-14 days). Microglia were separated from the cultures by shaking the flasks on a rotary shaker for 1.5 h at 260 rpm. Followed by an additional 18-h shake, OPCs were generated and astrocytes were adherent to the flasks. Astrocytes were suspended using 0.25 % trypsin/EDTA and then plated at 2×10 4 cells/mL in untreated six-well dishes. OPCs were seeded into poly-D-lysine (PDL)-coated T75 flasks at a density of 1.5×10 4 /cm 2 in a chemically defined media, N2S, composed of (1) 66 % N2B2 media, (2) 34 % B104 CM, (3) 5 ng/mL FGF-2, and (4) 0.5 % FBS. OPC cultures were amplified 4-10 days and passaged once using papain [29] prior to performing the experiments. A >95 % purity of early OPCs (A2B5+/O4−) was consistently achieved with these enrichment and culture conditions with <2 % contamination with astrocytes and <0.01 % contamination with microglia as previously reported [31] . Some early OPCs were allowed to mature into late OPCs (O4+/Rmab−) by replacing the N2S with 10 ng/ml FGF-2. For immunocytochemistry experiments, cells were plated at a density of 2.0 × 10 4 cells/cm 2 onto PDL-coated chamber slides in N2S media. Twelve to 15 h after plating for experiments, OPCs were switched to N1A serum-free media to arrest cells in G0/G1. N1A was identical to the N2B2 media described above, with the exception that the insulin concentration was lowered to 5 ng/mL. Cells were treated in N1A media for 6 h prior to growth factor treatment. The media were then replaced with the appropriate growth factors for 18 h followed by 2 h BrdU pulse.
Immunocytochemistry
For characterization studies, cells were fixed and stained with primary antibodies overnight at 4°C, including mouse IgM antibodies against PSA-NCAM (Millipore, Billerica, MA, USA; 1:500), A2B5 (supernatant 1:4), D1.1 (supernatant 1:4), R24 (supernatant 1:4), rabbit antibodies against Dlx2 (Millipore, 1:500), NG2 (generously provided by Bill Stallcup, 1:200), Olig2 (Millipore, 1:500), GFAP (Dako, 1:500), and mouse IgG against vimentin (V9 clone, Roche, 1:100). For the clonal analyses, spheroids were propagated and dissociated into single cells. Cells were plated onto PDL-coated chamber slides at 2 ×10 4 cells/well in (1) N2B2 + 2 % serum with 700 CFU/well or (2) ProN/ B104 +2 % serum with 50 CFU/well for 1 day. Media was then replaced with N2B2 for 5 days to allow differentiation. After live O4 staining, cells were fixed in 4 % PFA and stained for green fluorescent protein (Aves Labs, 1:2,500) and GFAP. For the differentiation experiments, cells were fed with either N2B2 media alone or N2B2 supplemented with combinations of recombinant rat VEGF 164 A (R&D Systems, 8 ng/mL) and recombinant human VEGF-C (Cys156Ser) (R&D Systems, 100 ng/mL). After treatment, the cells were fixed for 10 min in 4 % PFA and then incubated for 1 h at room temperature (RT) with primary antibodies described above against GFAP or O4 to identify astrocytes and oligodendrocytes, respectively. The cells were washed and further incubated with fluorochrome-labeled secondary antibodies for 1 h at RT.
For double labeling of BrdU and GFAP, O4, or PSA-NCAM, cells were pulsed with 10 μM BrdU for 2 h prior to staining. Fixed cells were pretreated in 2 N HCl for 15 min at RT to denature DNA and rinsed with borate buffer (pH 8.5). Cells were incubated for 30 min with 0.1 M Tris buffer/0.1 % Triton X-100 followed by a 20-min incubation with 10 % BSA and 10 % goat serum in Tris buffer. Cells were incubated in primary antibodies, rinsed, and then incubated in fluorochrome-conjugated secondary antibodies. The cells were counterstained with DAPI for 10 min. Stained cells were washed thoroughly and mounted with Gel/Mount (Biomeda, Foster City, CA, USA) and allowed to dry overnight. Immunoreactive cells were visualized using an Olympus AX70 microscope and images of stained cells were collected using a Photometrics cooled charged coupled device camera (Tucson, AZ, USA) interfaced with IP Lab scientific imaging software (Scanalytics, Inc.).
In all experiments, labeled cells in at least four random (nonadjacent) fields were counted per well under a ×20 or ×40 objective lens and a total of four wells per independent group were evaluated. At least 100 cells were counted based on DAPI staining for each experiment.
BrdU Immunohistochemistry
For the BrdU labeling experiment, BrdU (Sigma, at 50 mg/ kg body weight, 10 mg/mL in 0.007 N NaOH in 0.9 % NaCl) was administered intraperitoneally 4 h following H-I. Thirty minutes later, animals were sacrificed by intracardiac perfusion, cryoprotected, and frozen, and tissue sections encompassing the region of the brain subserved by the middle cerebral artery were cut at 12 μm thickness and mounted onto glass slides. Select tissue sections were incubated for 1 h at RT in 2 N HCl, extensively rinsed with borate buffer (pH 8.5), and blocked in a solution containing 10 % BSA and 10 % goat serum in Tris buffer for 1 h. The sections were then incubated with a rat monoclonal antiBrdU (Accurate Chemical, Westbury, NY, USA; 1:30) and biotinylated tomato lectin (Vector Laboratories, Burlingame, CA, USA; 1:100) overnight at 4°C. Sections were further incubated in fluorochrome-conjugated secondary antibodies (Jackson ImmunoResearch Laboratories; 1:200) for 2 h at RT. DAPI was used to stain all nuclei.
VEGF Receptor Blocking Studies
Purified early OPCs were starved in N1A medium (5 ng/ml insulin) for 6 h. OPCs were then incubated with VEGF-C (Cys156Ser) (R&D Systems; 100 ng/ml) and blocking antibodies to either VEGFR-1 (cat. no. AF471, R&D Systems, 5 μg/ml), VEGFR-2 (cat. no. AF644, R&D Systems, 0.2 μg/ml), VEGFR-3 (ImClone IMC-3C5, 7.5 μg/ml), or N2B2 medium control for 18 h. IMC-3C5 is an antagonist antibody for human VEGFR-3 with cross-reactivity to rat VEGFR-3 (ImClone Systems, unpublished data). After treatment, the OPCs were fixed for 10 min in 3 % PFA and then incubated with primary antibodies against Ki67 (Vector Laboratories, 1:1,000) and A2B5 (supernatant, 1:5) or O4 (supernatant, 1:4) to identify the proliferating oligodendrocyte at both early and late stages, respectively, at 4°C overnight. The OPCs were then rinsed and incubated in fluorochrome-conjugated secondary antibodies for 1 h at RT and counterstained with DAPI (Sigma, 1:5,000) for 10 min. After washing, slides were mounted with Gel/ Mount (Biomeda) and allowed to dry overnight. An Olympus AX70 microscope was used to collect images of immunopositive cells. In all experiments, labeled cells were counted in at least six random (nonadjacent) fields per well under a ×20 or ×40 objective lens and a total of four wells per independent group were evaluated. At least 500 cells were counted from each treatment group.
Statistical Analyses
Results from cell culture were analyzed for statistical significance using a Student's t test or by analysis of variance (ANOVA) with Fisher's partial least squares difference (PLSD) post hoc test. Error bars represent the standard errors of the mean (SEMs). Comparisons were interpreted as significant when associated with p<0.05.
Results
VEGFs are Quickly and Transiently Upregulated After Neonatal H-I in the SVZ Sandwich ELISA analyses for VEGF-A and VEGF-C proteins demonstrated induction by 12 and 24 h, respectively, compared to nonhypoxic shams and CL hemispheres (Fig. 1a, b) . However, both proteins quickly returned to baseline levels within 2 days after injury and remained so up to 7 days post-H-I. Neither VEGF-A, VEGF-B, nor VEGF-C mRNA levels increased after H-I (data not shown).
To determine which cell types may be responsible for producing VEGFs, we measured levels of VEGF-A and VEGF-C in culture supernatants from highly enriched astrocyte and microglial cultures. Astrocytes constitutively produced large quantities of VEGF-A, whereas the production of VEGF-A by the microglia was below the level of detection (Fig. 1) . Whereas the microglia did not produce detectable levels of VEGF-A, they did produce VEGF-C, and exposing the microglia to HG conditions increased their VEGF-C production. HG also tended to increase VEGF-C production by the astrocytes, although the increase was not statistically significant (p > 0.05). The supernatant from SVZ-derived spheroids was also analyzed and found to contain very high levels of VEGF-A, as well as some VEGF-C. These progenitors were grown under 2 % O 2 to mimic the in vivo niche and, thus, were not further subjected to HG conditions.
Effects of VEGFs on Glial Progenitors In Vitro
Several studies have shown that VEGF proteins can stimulate the proliferation of various neural cell types [16, 23, 25] . To determine the effects of VEGFs A and C on SVZ glial progenitors, spheroids were generated in ProN/B104 media for 7-10 days in 2 % O 2 . Spheroid cells were then exposed to recombinant VEGFs A and/or C overnight (18 h) and then incubated with 10 μM BrdU for 2 h to label cells entering the S-phase of mitosis. Spheres were dissociated gently and stained for PSA-NCAM and BrdU. Neither VEGF-A nor VEGF-C independently increased the percentage of PSA-NCAM+/ BrdU+ cells. The combination of VEGF-A and C showed a positive trend, which was not statistically significant (data not shown).
To determine how VEGF-A and VEGF-C affected cell differentiation, spheroids were generated and subsequently dissociated. Cells were differentiated for 3 days on PDLcoated chamber slides. VEGF-A increased the percentage of GFAP+ cells, while VEGF-C increased the percentage of O4+ cells after 3 days of differentiation in vitro (Fig. 2a-d ).
There was a small percentage of cells that remained unlabeled after differentiation.
To determine whether the VEGFs were affecting the differentiation of the spheres or the proliferation of specific precursors, we performed the same 3-day differentiation experiment with a 4-h BrdU pulse prior to fixation and immunocytochemistry. Both VEGF-A and VEGF-C significantly increased BrdU incorporation in spheroids (Fig. 2e) . VEGF-A administration increased BrdU incorporation in the GFAP+ population in spheroids, while VEGF-C did not have any significant effect on BrdU incorporation in the GFAP+ cells. On the other hand, only VEGF-C significantly increased BrdU incorporation of the O4+ population, and this effect was dampened by the addition of VEGF-A to the condition. When both VEGFs were added to the cultures, there was still a significant increase in total BrdU incorporation from the control, which was mostly within the GFAP+ cell population.
Effects of VEGFs on Neonatal Lineage-Restricted Glial Progenitor Cells
We were also interested in whether these VEGFs would induce the proliferation of more lineage-restricted glial cell precursors. To address this question, we generated enriched astrocyte and OPC cultures and treated them overnight (18 h) with VEGFs A and/or C followed by a 2-h BrdU dose. In the astrocyte cultures, both VEGF-A and VEGF-C had significant proliferative effects on the GFAP+ cells individually, and the combined treatment revealed an additive proliferative effect (Fig. 3a) .
In enriched early OPCs, an overnight treatment with 8 ng/ mL of VEGF-A did not affect BrdU incorporation; however, Fig. 1 VEGF-A and VEGF-C protein expression. a, b ELISAs were performed for VEGF-A (a) and VEGF-C (b) on protein samples isolated from microdissected SVZs at time points varying from 12 h to 7 days after neonatal H-I (n04 per sample). Error bars represent the SEM. *p<0.05, using Student's t test between ipsilateral (IL) and both contralateral (CL) and nonhypoxic control (NHC) hemisphere protein samples. c ELISAs were performed on supernatants from glial progenitor spheroids (GP), astrocytes, and microglia. Spheroids were continuously grown in 2 % oxygen, and astrocytes and microglia were exposed to 2 % oxygen and glucopenic conditions for 2 h (HG). Media was collected 24 h after returning the cells to atmospheric, normoglycemic (control) conditions, n04 for each condition. Error bars represent the SEM. *p<0.05, significant t test between control and HG conditions for each cell type overnight treatment with 100 ng/mL VEGF-C significantly increased BrdU incorporation, with a robust doubling of cells passing though the S-phase (Fig. 3b) . Adding VEGF-A with VEGF-C significantly dampened this proliferative response. These results support the conclusion that VEGF proteins have significant proliferative effects on lineage-restricted cell types isolated from the neonatal rat brain.
Spheroids Express Higher Levels of VEGFR-3 than Glial-Restricted Cells VEGFR-3 is exclusive to VEGF-C signaling compared to VEGFR-2, which can be activated by multiple members of the VEGF ligand family. Since VEGF-C stimulated the proliferation of OPCs and VEGF-C can bind to both VEGFR-2 Representative image of cells maintained in N2B2, VEGF-A, and VEGF-C and stained for O4 (red), GFAP (green), and DAPI (blue) in b. Graphs depict averaged data from counting at least 100 cells from 4 wells for each treatment. Error bars represent the SEM. *p<0.05, compared to control conditions using Student's t test. c BrdU (10 μM) was added to the media during the last 4 h of incubation with growth factors. Cells were stained for O4, GFAP, BrdU, and DAPI (c). Graphs depict averaged data from counting at least 100 cells from 4 wells for each treatment. Data are representative of two to three independent experiments. Error bars represent the SEM. *p<0.05, ANOVA with Fisher's PLSD post hoc test and VEGFR-3, we sought to establish whether OPCs expressed the VEGFR-3 and to compare the level of VEGFR-3 on OPCs versus other neural precursors. Protein samples from neurospheres, spheroids, astrocytes, early OPCs, and late OPCs were separated by gel electrophoresis transferred to nitrocellulose and probed for VEGFR-3 by Western blot. Interestingly, the spheroids, which are comprised of tripotential PDGF-responsive progenitors (Moore et al., submitted), expressed the highest levels of VEGFR-3 with the rank order of spheroids>neurospheres>early OPCs> late OPCs>astrocytes (Fig. 4a) .
Neutralizing the VEGFR-3 Abolished VEGF-C-Stimulated Oligodendrocyte Proliferation
To establish whether the proliferative effects of VEGF-C were indeed conveyed by VEGFR-3, experiments were conducted using neutralizing antibodies to VEGFR-1, VEGFR-2, and VEGFR-3. For these experiments, early OPCs were incubated with either VEGF-C or neutralizing antibodies to VEGFR-1, VEGFR-2, or VEGFR-3. Cell proliferation was evaluated by double immunostaining for Ki67 with either A2B5 or O4 antibody. As expected, VEGF increased the Ki67 index of both early OPCs and late OPCs and the neutralizing antibody Fig. 3 VEGF-A and VEGF-C cooperate to stimulate astrocyte proliferation, but only VEGF-C alone stimulates OPC proliferation. a Astrocytes from neonatal mixed glial cultures were plated onto chamber slides overnight in N2B2 alone or supplemented with 8 ng/mL VEGF-A and/or 100 ng/mL VEGF-C. After 18 h, BrdU was added, and 2 h later, the cells were fixed and stained for BrdU, GFAP, and DAPI. b OPCs were generated from mixed glial cultures and plated onto chamber slides overnight in N2B2 with 0.5 % serum, followed by a 6-h starvation period. Then, media were supplemented with 8 ng/mL VEGF-A and/or 100 ng/mL VEGF-C, and 10 μM BrdU was added during the final 2 h of an 18-h treatment. Chamber slides were fixed and stained for BrdU, O4, and DAPI. Graphs represent averaged data from counting at least 100 cells from 4 wells for each treatment. Data are representative of two to three independent experiments. Error bars represent the SEM. *p<0.05, compared to control conditions using ANOVA analysis with Fisher's post hoc test Fig. 4 VEGFR-3 is expressed by neural precursors and blocking VEGFR-3, but not VEGFR-1 or VEGFR-2, abolishes VEGF-C-stimulated oligodendrocyte proliferation. a Neurospheres and spheroids were generated from neonatal rat SVZs and cultured for 7 DIV in 2%O 2 , 5 % CO 2 , and 93 % N 2 . Astrocytes and OPCs were generated from mixed glial cell cultures from neonatal rat brains. Fibroblasts (3T3) were grown in 10 % serum containing medium. Expression of VEGFR-3 (Flt-4) (175 kDa) was evaluated by Western blot. Data are representative of three independent experiments. b-u Early OPCs were incubated with either VEGF-C (100 ng/ml) or neutralizing antibodies to VEGFR-1 (5 μg/ml), VEGFR-2 (0.2 μg/ml), or VEGFR-3 (7.5 μg/ ml) in N2B2 medium. Cells were double immunostained for Ki67 with either A2B5 or O4 and counterstained with DAPI (b-u). VEGF-C promoted the proliferation of both early OPCs (c, h) and late OPCs (m, r), compared with N2B2 control medium (b, g, l, q). The neutralizing antibody to VEGFR-3 completely blocked VEGF-C-stimulated OPC proliferation (f, k, p, u). In contrast, neutralizing antibodies to VEGFR-1 or VEGFR-2 did not inhibit VEGF-C function (d, i, n, s and e, j, m, t). Scale bar represents 50 μM. v, w Quantification of both A2B5+ (v) and O4+ (w) OPCs, *p<0.05 by ANOVA followed by Fisher's post hoc test to VEGFR-3 completely blocked the VEGF-C-stimulated OPC proliferation (Fig. 4b-u) . In contrast, neutralizing antibodies to VEGFR-1 or VEGFR-2 did not inhibit VEGF-C function (Fig. 4v, w) .
SVZ Microvasculature Remodeling After Injury
Since the levels of these angiogenic growth factors were increased during the acute recovery interval from neonatal H-I, it was of interest to evaluate microvasculature alterations within the SVZ after neonatal H-I. Hematoxylin and eosin staining was performed on sections 4 to 48 h after H-I and measurements were made of the luminal areas of vessels in the SVZ. At 4 h after injury, there were robust increases in the luminal areas of microvessels in the IL SVZ compared to nonhypoxic (74-fold) and CL (4-fold) hemispheres, respectively, which remained significantly higher until at least 48 h after injury (Fig. 5) . As this increase in luminal area could either be due to the vasodilatory effects of hypoxia or to angiogenesis, we administered BrdU at 4 h after H-I and then performed immunohistochemical staining using tomato lectin and BrdU. Contrary to the hypothesis that the increase in VEGFs would result in increases in angiogenesis, there was no difference in BrdU incorporation into the endothelial cells within the SVZ (data not shown). These data suggest that the increased luminal area observed in the injured SVZ as early as 4 h after injury is not a consequence of angiogenesis, but rather more likely due to vessel dilation.
Discussion
The goal of this study was to determine whether VEGFs A or C participate in the reactive responses of the progenitors in the SVZ to neonatal H-I. We found that (1) both VEGFs A and C are quickly and transiently induced in the SVZ during recovery from H-I; (2) glial progenitors, astrocytes, and to a lesser extent, microglia, produce these growth factors; (3) VEGFs A and C differentially affect the production of astrocytes and oligodendrocytes from SVZ-derived spheroids; (4) VEGFs A and C stimulate the proliferation of lineage-restricted astrocyte and OPCs; and (5) VEGF-C exerts its proliferative effects on OPCs via the VEGFR-3 receptor.
A collection of studies in Cell Stem Cell highlighted the importance of the neurovascular stem cell niche during development [32] [33] [34] [35] . The studies independently examined the intimate relationship between the cerebral vasculature and the neural stem and progenitor cell compartments. We were also interested in evaluating the neurovascular niche of the SVZ after neonatal H-I during the period when we have previously observed proliferative changes in the SVZ cells. We found that two angiogenic proteins, VEGFs A and C, are quickly and transiently increased in the SVZ. Attempts to use immunohistochemistry to establish which cells within the neonatal SVZ were producing these cytokines were ambivalent. We used a previously established in vitro model for the multipotential progenitor fraction of the neonatal SVZ to determine how VEGFs would affect their proliferation and differentiation (Moore et al., 2012, accepted pending minor revision). Next, ELISAs for VEGF-A and VEGF-C were used to measure the production of these factors from astrocytes, microglia, and spheroids. We found that the spheroids produced large amounts of both proteins. Astrocytes produced both VEGF-A and VEGF-C, and under HG conditions, there were slight increases in the protein production. Microglia were a source of VEGF-C, which was significantly upregulated after HG conditions. Unfortunately, we were unable to compare the amounts of proteins produced by each cell type, as we were limited by our culture techniques and unable to normalize the number of cells in a spheroid and the different plating densities of astrocytes and microglia.
In this study, we found that VEGFs A and C had different effects on multipotential progenitors in the spheres versus more mature glial precursors. When applied to the spherederived cells, neither VEGF-A nor VEGF-C altered the percentage of PSA-NCAM+ cells and they were weak mitogens for these cells, unlike studies of NSCs stimulated by VEGF-A [15, 36, 37] . However, we did find that VEGF-A promoted astrocyte proliferation, supporting many studies relating VEGF-A signaling via the R2 receptor (Flk-1) to astrogliogenesis and scar formation after brain injury Morphometric analysis was performed on ×40 images of corresponding vessels in the SVZ using IP Lab (Scanalytics, Inc.). Sections from 4-h brains were stained for BrdU (red), tomato lectin (green), and DAPI (blue) to label proliferating blood vessels (white arrowheads) in IL (c) and CL (e) hemispheres. IL ipsilateral hemisphere, CL contralateral hemisphere, NHC nonhypoxic control, V ventricles. n08 vessels measured from three random, nonadjacent SVZ sections and four animals at each time point. Error bars represent the SEM. *p<0.05, compared to both CL and NHC [38] [39] [40] . Moreover, these studies provide evidence that VEGF-A can also affect the astrocyte generation from the SVZ, near the VEGF-producing choroid plexus [37, 41] . We also found VEGF-C supported oligodendrocyte production both in spheroid cultures and forebrain OPC cultures, similar to the trophic effects of VEGF on optic nerve OPCs [25] . When these growth factors were applied together to enriched astrocyte cultures, they exerted additive proliferative effects. By contrast, combined treatment to OPCs actually decreased the stimulatory effect of VEGF-C on OPC proliferation. These effects are most likely due to differential expression of the VEGF receptors on different glial cell types. In this study, we did establish that VEGFR-3 is present in the neonatal SVZ. We were unable to obtain comparison levels of R1 or R2 in this study; however, this may have clouded our results and conclusions given the cross talk of VEGF-A and VEGF-B ligands with both of these receptors.
The vascular cells of the SVZ are appreciated as important components of the stem cell microenvironment. The microvascular system can exert effects on the growth, survival, differentiation, and migration of stem and progenitor cells [18] . As we found that two potent growth factors that affect vascular elements are increased in the SVZ as a consequence of injury, we asked whether there were corresponding changes in the cerebrovasculature of the SVZ. At 4 h after injury, we found a significant increase in the luminal diameter of the IL SVZ microvasculature, compared to both the CL and NHCs. However, when we looked at BrdU incorporation at this early time point, we did not find any significant changes in the injured SVZ, suggesting that neovasculogenesis is not the cause of the increased luminal area. More likely, other signaling molecules, such as nitric oxide (NO), possibly induced by VEGF proteins, have effects on smooth muscle cells in the region, causing relaxation of the vasculature. These signaling molecules may also play a role in the NSC niche. For example, NO has been found to inhibit the proliferation of NSCs in the SVZ, as well as promote neuronal differentiation [42, 43] . Given that VEGFs A and C are present in the injured SVZ for up to 24 h after insult, these proteins may play alternative, nonangiogenic roles during recovery.
Glial scarring is a well-characterized consequence of brain injury. In the mature brain, data suggest that the majority of reactive astrocytes arise from existing astrocytes residing in the penumbra of the injury as a consequence of cytokines produced by damaged neurons and reactive microglia [44] [45] [46] . Histopathologic studies on the brains of infants who have expired from neonatal H-I have shown that there is significant gliosis in affected regions [47] . However, in the immature brain where astrocyte genesis is incomplete, this explanation for the origin of reactive astrocytes cannot completely explain their generation. We have found that VEGF-A and VEGF-C can collaborate to stimulate the expansion of SVZ glial progenitors and that they will increase the production of astrocytes both from SVZ multipotential progenitors as well as from immature astrocytes. These studies confirm that VEGF-A is important for astrogliogenesis, especially after neonatal H-I [16, 39, 40] . However, these studies also extend the role of VEGF-A to having specific effects of SVZ progenitors to generating more astrocytes instead of the more developmentally appropriate oligodendrocytes. In a 2010 study in adult rats, VEGFR-3 was noted to be expressed by multiple progenitor cell types in the SVZ after hypoxic injury, including cells positive for PSA-NCAM, nestin, and GFAP [48] . Moreover, these cells were highly proliferative, suggesting that VEGFR-3 was an important mediator in adult neurogenesis after ischemic stroke.
In our studies, we show that VEGF-C does exert specific effects on oligodendrocytes of the SVZ, extending the studies by Le Bras et al. that VEGF-C, mediated by VEGFR-3, is important for OPC survival and differentiation. Furthermore, we also found VEGFR-3 to be a crucial mediator in VEGF-C signaling for OPC proliferation and differentiation. By blocking VEGFR-3 in vitro, we abolished the effects of VEGF-C on OPC cultures. On the other hand, the blocking of VEGFR-1 and VEGFR-2 did not have the same effect. This important distinction may elucidate other mechanisms that may be occurring after H-I injury in the neonatal brain. These distinctions may eventually be a target for pharmacologic or gene therapy interventions after injury. Altogether, these results provide new evidence for a role for VEGFs in remodeling the SVZ after neonatal injury. In particular, they provide insights into the origins of the reactive astrocytes that appear during recovery from neonatal H-I. Our studies further suggest that therapeutics that can extend VEGF-C expression or agonists that can stimulate the VEGFR-3 will enhance the production of OPCs to promote myelination after perinatal brain injury.
